Blazing a New Path in Medicine

Nurix is committed to bringing novel, first-in-class therapies to patients without adequate treatment options. Our small molecule drugs are designed to modulate protein levels in cells as a new therapeutic approach for cancer.

Nurix was founded by a team of internationally renowned experts in the fields of E3 ubiquitin ligase regulation and structure. Since its incorporation, Nurix has built a seasoned team of leaders with wide-ranging backgrounds in small molecule drug development and cancer therapy. Through its leadership in Targeted Protein Modulation and its powerful proprietary DELigase platform, Nurix has attracted industry-leading partners, including its current drug discovery collaborations with Gilead Sciences, Sanofi, and Pfizer.